-
公开(公告)号：KR1020140102596A
公开(公告)日：2014-08-22
申请号：KR1020130158104
申请日：2013-12-18
Applicant: 중앙대학교 산학협력단
IPC: A61K9/16 , A61K9/14 , A61K47/48 , C12N15/115
CPC classification number: C12N15/115 , A61K47/549 , A61K47/6923 , A61K47/6929 , C12N2310/16 , A61K9/16 , A61K9/14 , A61K47/50
Abstract: The present invention relates to a protein transduction domain comprising gold nanoparticles and aptamers binding to the surface of the gold nanoparticles. The protein transduction domain according to the present invention is expected to be useful for diagnosing or treating diseases, since the protein transduction domain effectively delivers the proteins into cells by specifically binding to proteins which are to be delivered by various tagged aptamers or protein-specific aptamers binding to gold nanoparticles, can be harmless to a human body by using gold nanoparticles having very little cytoxitity, and allows easy confirmation of the intercellular position by reflecting lights of various wavelengths.
Abstract translation: 本发明涉及包含金纳米颗粒和与金纳米粒子表面结合的适体的蛋白质转导结构域。 预期根据本发明的蛋白质转导结构域可用于诊断或治疗疾病，因为蛋白质转导结构域通过特异性结合将被各种标记的适配体或蛋白质特异性适体递送的蛋白质而有效地将蛋白质递送到细胞中 与金纳米颗粒结合，可以通过使用具有极少细胞毒性的金纳米颗粒对人体无害，并且通过反射各种波长的光可以容易地确认细胞间位置。
-
12.发明授权ＣｏｌＥ1-타입 플라스미드의 복제수를 증가시키는Ｎ-Ｒｎｅ 변이체(Ｎ-Ｒｎｅ-Ｑ36Ｒ) 및 이를 코딩하는ＤＮＡ 有权N-Rne突变体N-Rne-Q36R增加ColE1型质粒的拷贝数和编码它们的DNA
公开(公告)号：KR100961720B1
公开(公告)日：2010-06-10
申请号：KR1020070110114
申请日：2007-10-31
Applicant: 중앙대학교 산학협력단
Abstract: 본 발명은 서열번호: 1의 아미노산 서열을 갖는 N-Rne(RNase E catalytic domain) 변이체, 및 상기 변이체를 코딩하는 DNA에 관한 것으로, 본 발명의 변이체는 ColE1-타입의 복제원점을 포함하는 플라스미드의 복제수를 필요에 따라 효과적으로 증폭할 수 있어 플라스미드 DNA의 대량 정제가 가능하다.
ColE1-타입 플라스미드, RNase E, N-Rne 변이체-
13.发明公开ＣｏｌＥ1-타입 플라스미드의 복제수를 증가시키는Ｎ-Ｒｎｅ 변이체(Ｎ-Ｒｎｅ-Ｑ36Ｒ) 및 이를 코딩하는ＤＮＡ 有权N-RNE突变体（N-RNE-Q36R）增加COLE1型PLASMID的拷贝数和编码其的DNA
公开(公告)号：KR1020090044158A
公开(公告)日：2009-05-07
申请号：KR1020070110114
申请日：2007-10-31
Applicant: 중앙대학교 산학협력단
Abstract: 본 발명은 서열번호: 1의 아미노산 서열을 갖는 N-Rne(RNase E catalytic domain) 변이체, 및 상기 변이체를 코딩하는 DNA에 관한 것으로, 본 발명의 변이체는 ColE1-타입의 복제원점을 포함하는 플라스미드의 복제수를 필요에 따라 효과적으로 증폭할 수 있어 플라스미드 DNA의 대량 정제가 가능하다.
ColE1-타입 플라스미드, RNase E, N-Rne 변이체-
Patent Agency Ranking
公开(公告)号：KR102120659B1
公开(公告)日：2020-06-11
申请号：KR1020180067087
申请日：2018-06-11
Applicant: 중앙대학교 산학협력단
IPC: C12Q1/6886 , A61K31/7105
-
公开(公告)号：KR101966505B1
公开(公告)日：2019-04-05
申请号：KR1020160164246
申请日：2016-12-05
Applicant: 중앙대학교 산학협력단 , 조선대학교산학협력단
-
16.发明授权글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물 有权包含用于预防或治疗卵巢颗粒细胞肿瘤的GLYCOGEN SYNTHASE KINASE 3-BETA抑制剂的药物和食品组合物
公开(公告)号：KR101440724B1
公开(公告)日：2014-09-18
申请号：KR1020130034672
申请日：2013-03-29
Applicant: 중앙대학교 산학협력단
IPC: A61K31/40 , A61K31/404 , A61K31/4035 , A61P35/00
CPC classification number: A61K31/426 , A23L33/10 , A23V2002/00 , A61K31/404
Abstract: The present invention relates to a pharmaceutical composition or a health functional food composition comprising, as an active ingredient, any one selected from a group consisting of a compound expressed by Chemical Formula 1, a pharmaceutically acceptable salt of the compound expressed by Chemical Formula 1, a compound expressed by Chemical Formula 2, and a pharmaceutically acceptable salt of the compound expressed by Chemical Formula 2 for preventing or treating granular cell tumor of ovary. By comprising any one selected from a group consisting of a compound expressed by Chemical Formula 1, a pharmaceutically acceptable salt of the compound expressed by Chemical Formula 1, a compound expressed by Chemical Formula 2, and a pharmaceutically acceptable salt of the compound expressed by Chemical Formula 2 as an active ingredient, the composition of the present invention inhibits Glycogen synthase kinase 3-beta (GSK3beta) to thereby have an effect of inhibiting phosphorylation of serine, which is a 33rd amino acid of forkhead box L2 (FOXL2) protein. Therefore, the composition of the present invention can be useful as a composition for preventing or treating granular cell tumor of ovary. In addition, it is expected that the composition of the present invention can be useful as a health functional food composition.
Abstract translation: 本发明涉及一种药物组合物或保健功能食品组合物，其包含作为活性成分的选自由化学式1表示的化合物，由化学式1表示的化合物的药学上可接受的盐， 由化学式2表示的化合物和由化学式2表示的化合物的药学上可接受的盐，用于预防或治疗卵巢的颗粒细胞瘤。 通过包含选自由化学式1表示的化合物，由化学式1表示的化合物的药学上可接受的盐，由化学式2表示的化合物和由化学式表达的化合物的药学上可接受的盐中的任何一种 式2作为活性成分，本发明的组合物抑制糖原合酶激酶3-β（GSK3β），从而具有抑制作为叉头盒L2（FOXL2）蛋白的第33位氨基酸的丝氨酸磷酸化的作用。 因此，本发明的组合物可用作预防或治疗卵巢颗粒细胞肿瘤的组合物。 此外，预期本发明的组合物可用作健康功能性食品组合物。
-
公开(公告)号：KR1020170015715A
公开(公告)日：2017-02-09
申请号：KR1020150108251
申请日：2015-07-30
Applicant: 재단법인 아산사회복지재단 , 중앙대학교 산학협력단
Abstract: 본발명은암의치료또는진단을위한 LRIG2의용도에관한것이다. 상세하게는, 본발명은 LRIG2(leucine-rich repeats and immunoglobulin-like domains 2) 유전자또는상기유전자가코딩하는단백질을유효성분으로포함하는자궁내막암의예방또는치료용약학적조성물, 자궁내막암진단용바이오마커, 자궁내막암진단용조성물, 자궁내막암진단용키트, 및자궁내막암치료제의스크리닝방법을제공한다.
-
公开(公告)号：KR1020090035153A
公开(公告)日：2009-04-09
申请号：KR1020070100265
申请日：2007-10-05
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
Abstract: N-Rne mutant and a copy number-controllable cloning vector comprising a DNA encoding same are provided to refine DNA plasmid massively according to the necessary copy number of the plasmid and to control expression of target protein. A plasmid pCNR1H includes an RNase E catalytic domain having a nucleotide sequence of a sequence number 2 and a replication origin of a ColE1- type and a mutant DNA. The plasmid pCNR1H comprises more the restriction enzyme site for inserting a target gene in control of a lactose promoter, a selectable marker, an arabinose promoter controlling expression of the DNA.
Abstract translation: 提供N-Rne突变体和包含编码该DNA的拷贝数可控克隆载体，以根据质粒的必需拷贝数大量细化DNA质粒，并控制靶蛋白的表达。 质粒pCNR1H包括具有序列号2的核苷酸序列和ColE1-型复制起点和突变型DNA的核糖核酸酶E催化结构域。 质粒pCNR1H在控制乳糖启动子，选择性标记，控制DNA表达的阿拉伯糖启动子中含有更多的用于插入靶基因的限制酶位点。
-
-
-
-
-
-
-
Search Results
18
records
(took 0.024 seconds)
